Table 1.
Characteristics of the enrolled patients in this study
| Characteristics | Results (n = 77) |
|---|---|
| Females | 41 (53) |
| Age (years) | 57 ± 12 |
| WHO functional class | |
| WHO FC I–II | 37 (48) |
| WHO FC III–IV | 40 (52) |
| Treatment | |
| Diuretics | 77 |
| Anticoagulants | 77 |
| Sildenafil | 7 |
| Biomarker at baseline | |
| Total bilirubin (µmol/L) | 22.2 ± 15.4 |
| Direct bilirubin (µmol/L) | 8.6 (2.3, 10.4) |
| Indirect bilirubin (µmol/L) | 13.5 ± 7.6 |
| GGT (U/L) | 78.7 (37.0, 94.5) |
| ALT (U/L) | 27.4 (18.0, 32.5) |
| AST (U/L) | 29.5 (19.0, 35.3) |
| Uric acid (µmol/L) | 360 ± 139 |
| NT-proBNP (pg/ml) | 2189 (672, 3627) |
| Hemodynamic and exercise capacity | |
| 6MWD (m) | 321 ± 103 |
| CVP (mmHg) | 8.5 ± 5.3 |
| sPAP (mmHg) | 87 ± 17 |
| mPAP (mmHg) | 50 ± 10 |
| PVR (wood units) | 14.4 ± 6.4 |
Data are shown as n (%), mean ± SD or median (IQR). WHO FC: World Health Organization functional class; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma-glutamyl transpeptidase; 6WMD: 6-min walk distance; CVP: Central venous pressure; sPAP: Systolic pulmonary artery pressure; mPAP: Medium pulmonary artery pressure; and PVR: Pulmonary vascular resistance; IQR: Interquartile range; SD: Standard deviation.